By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences has received notice from Nasdaq that it is not in compliance with a requirement to remain listed on the exchange.

In a document filed with the US Securities and Exchange Commission on Friday, Pressure Bio said that on Aug. 15, Nasdaq had notified it of its failure to comply with a listing requirement calling for a minimum bid price of $1 per share for 30 consecutive business days.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.